Outlook Therapeutics Inc(OTLK) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 5:12 PM ET (Korea 10/31 06:12)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 12.64% | Shs Outstand | 243.4M | Perf Week | -9.86% |
| Market Cap | 0.11B | Forward P/E | - | EPS next Y | 63.02% | Insider Trans | 61.78% | Shs Float | 212.7M | Perf Month | -18.59% |
| Enterprise Value | 0.12B | PEG | - | EPS next Q | -0.07 | Inst Own | 27.22% | Short Float | 15.32% | Perf Quarter | -48.73% |
| Income | - | P/S | - | EPS this Y | 73.18% | Inst Trans | 20.64% | Short Ratio | 3.18 | Perf Half Y | 78.53% |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 32.59M | Perf YTD | -70.37% |
| Book/sh | -0.06 | P/C | 10.14 | EPS past 3/5Y | 33.96% 33.18% | ROE | - | 52W High | -81.55% ($2.54) | Perf Year | -62.25% |
| Cash/sh | 0.05 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 190.56% ($0.16) | Perf 3Y | -95.69% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 86.28% | Gross Margin | - | Volatility(W/M) | 8.5% 9.42% | Perf 5Y | -98.87% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.05 | Perf 10Y | -99.93% |
| Dividend Ex-Date | - | Quick Ratio | 0.63 | EPS Q/Q | 90.1% | Profit Margin | - | RSI (14) | 36.01 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.81 | Sales Q/Q | - | SMA20 | -12.79% ($0.54) | Beta | 0.73 | Target Price | $5.03 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/14 | SMA50 | -21.97% ($0.6) | Rel Volume | 0.46 | Prev Close | $0.49 |
| Employees | 17 | LT Debt/Eq | - | EPS/Sales Surpr. | -12.5% -99.07% | SMA200 | -29.37% ($0.67) | Avg Volume(3M) | 10.24M | Price | $0.47 |
| IPO | 2016/6/14 | Option/Short | Yes/Yes | Trades | 3305 | Volume | 4,721,070 | Change | -5.15% |
💊 This U.S. biotech company is focused on developing antibody-based therapeutics for ophthalmic (eye) diseases. Its lead candidate, an ophthalmic formulation of bevacizumab (brand name LYTENAVA), targets the treatment of wet age-related macular degeneration (AMD) and has already received marketing authorization in Europe and the UK, entering the commercialization stage. The U.S. regulatory approval process is currently underway.
Over the past 1 year, on the lower side
81% below its 1-year high.
Traded less than usual. That is 46% of its average volume.
Earnings are growing steadily
Earnings are expected to grow by +73.2% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.9%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 27.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #340 of 595 in the industry
Based on market cap of $114M.
HUMA#339 Humacyte Inc $114M PER - OTLK#340 Outlook Therapeutics Inc $114M PER - 
NKTX#341 Nkarta Inc $112M PER - 
NERV#342 Minerva Neurosciences Inc $111M PER - 
AVXL#343 Anavex Life Sciences Corp $110M PER - 
FAQ
What kind of company is OTLK?
OTLK belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of OTLK?
The market cap of OTLK is approximately $114M, ranking 4,384 within its sector.
What is the 52-week high and low for OTLK?
OTLK has recorded a 52-week high of $2.54 and a low of $0.16.
